Blend · Vial
Verified record10mg
A two-peptide blend used to explore how different signals influence the body’s growth-hormone system.
Current batchCJCIPA 002-028
Published result99.1% reported purity
EternaGen / KLOW 002-009Blend · Research use only
Klow Blend
$220CAD
A four-peptide blend for laboratory research spanning tissue, skin and inflammatory-signalling models.
Purchasing review required
Select strength
1
Can’t find the right record?Send support the product name or batch code.
Contact supportProduct information
Klow Blend, clearly explained.
A four-peptide blend for laboratory research spanning tissue, skin and inflammatory-signalling models.
Overview
Klow contains BPC 157, GHK-Cu, TB-500 and KPV. The ingredients have been studied separately in very different settings, but the full blend’s stability, interactions and effects have not been established.
The label identifies an 80 mg fixed blend containing BPC 157 10 mg, GHK-Cu 50 mg, TB-500 10 mg and KPV 10 mg. The scientific record belongs to the individual molecular entities and study conditions—not to the blend name.- Format
- Vial
- Available strengths
- 80mg
- Batch
- KLOW 002-009
- Purity
- Verified
Research at a glanceComponent-level evidence only; four-compound blend not clinically established
Reviewed 23 July 2026View research context Declared blend composition
- BPC 157 — 10 mg
- GHK-Cu — 50 mg
- TB-500 — 10 mg
- KPV — 10 mg
The blend has not been studied as a whole. Research on one ingredient cannot predict how the complete mixture will behave.
Specifications
Product details
- Sequence / identity
- Confirm in batch record
- Molecular formula
- Confirm in batch record
- Molecular weight
- Confirm in batch record
- Storage and handling
- Consult the physical product label and digital batch record before laboratory handling.
Batch documentationVerified record available
Review the analytical record connected to this exact batch.
- Batch
- KLOW 002-009
- Purity
- Verified
Important research-use boundary
Health Canada lists the named compound or components among unauthorized injectable drugs identified in the Canadian market. A research-use label does not make an unauthorized product suitable or legal for personal use.
Explore the research
What has been studied?
Keep the context attached
Check what was studied, what researchers observed, and the limitation attached to each finding.
Question 01
Connective-tissue models
BPC 157 and GHK-Cu appear in separate tendon, fibroblast and wound-related experiments.
Evidence so far: Mostly preclinical or route-specificQuestion 02
Inflammatory signalling
KPV has been studied in epithelial cells and murine colitis models, not adequate human trials.
Evidence so far: Cell and animal evidenceQuestion 03
Fixed-mixture evidence
No controlled study was identified for the complete 10:50:10:10 mixture.
Evidence so far: Direct evidence absentProposed mechanism
How researchers are investigating the mechanism.
The named components have been investigated across connective-tissue, matrix-remodelling and inflammatory signalling models. Those pathways overlap conceptually, but that does not demonstrate synergy, compatibility or a combined outcome.
Study records
What was studied—and what was not.
See what researchers tested, what they observed and the limitation attached to each result.
Study 01Component-level evidence comparison
- What researchers saw
- Each component has a different evidence ceiling, from cell work to narrow topical human data.
- Why that is not the whole story
- Component plausibility does not establish blend synergy, safety, stability or benefit.
Study 02KPV murine colitis models
- What researchers saw
- Investigators reported reduced inflammatory measures under the experimental conditions.
- Why that is not the whole story
- Mouse colitis data do not establish a clinical effect, a systemic route or a four-compound protocol.
Evidence gaps
What remains unknown?
- Blend-specific stability, interactions, degradation products and analytical specificity require direct testing.
- No established human benefit-risk profile exists for the mixture.
- A batch record can document measured identity or purity; it cannot supply missing clinical evidence.
Primary sources
Check the original sources.
- Component evidence mapEternaGen Evidence by Compound records for BPC 157, GHK-Cu, TB-500 naming and KPV.
- Primary KPV studyKannengiesser et al. KPV in murine inflammatory-bowel-disease models. Inflamm Bowel Dis. 2008. PMID 18092346.
- Canadian public advisoryHealth Canada. Advisory on unauthorized injectable peptides. 2026.
Related products
Continue comparing.
Blend · Pen
Verified recordGlow Blend
$20070mg
A three-peptide blend for laboratory research into tissue repair, skin biology and connective-tissue signalling.
Current batchGLOW 003-017
Published resultVerified